|Videos|March 29, 2021

Dr. Scott T. Tagawa on radium-223 in prostate cancer

Scott T. Tagawa, MD, highlights pivotal research and next steps with the alpha particle–emitting radioactive therapeutic agent radium-223 in prostate cancer.

Scott T. Tagawa, MD, provides expert insight on radium-223 (Xofigo), highlighting pivotal research and next steps with the alpha particle–emitting radioactive therapeutic agent. Tagawa is a professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME